BridgeBio Pharma (BBIO) PT Raised to $110 at TD Cowen

August 11, 2026 8:04 AM

TD Cowen analyst Tyler Van Buren raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $110.00 (from $95.00) while maintaining a Buy rating.

No results found